Veterinary Practice Valuation & EBITDA Multiples
Veterinary practices sell for 4x–14x adjusted EBITDA in 2026 — but doctor count explains most of the spread: solo caps at 3.5–6x while 3+ DVM practices with $1M+ EBITDA clear 12–15x from PE consolidators.
Updated 2026-06-05·14 min read·Healthcare Services & IT
Adjusted EBITDA multiple
4.0x – 14.0x
Typical: 8.5x · Sample: Triangulated from Ackerman Group Q1/Q2 2025 reports, SovDoc 2025, Transitions Elite/PetVet pricing disclosures, Octus VSO 2025 coverage, and the SVP/MVP Dec 2024 platform print; valid as of 2026-06-05
- Adj. EBITDA range
- 4.0x – 14.0x
- Typical multi-doctor GP add-on
- 7–9x
- SVP + MVP recap, Dec 2024
- 17–18x
- Vet invoice growth, 2022–2024
- −2%/yr
Quick answer
Veterinary practices typically sell for 4x to 14x adjusted EBITDA, with the single biggest variable being doctor count. Solo, owner-dependent practices cap at 3.5–6x and sell to individual SBA-funded buyers. Multi-doctor (3–4+ DVMs) GPs with $750K+ EBITDA clear 7–9x from regional consolidators, and $1M+ EBITDA practices reach 12–15x from PE-backed platforms [1][7]. Specialty and emergency hospitals — where corporate ownership is now ~75% of the market — trade at 12x+ as a baseline, and recap-tier platforms (Mission Pet Health / SVP + MVP) priced at 17–18x EBITDA in the December 2024 mega-merger [3][6].
The page-wide macro caveat: US veterinary invoice growth has been negative three years running (2022, 2023, 2024) — the variable Ackerman Group says will determine recap multiples for years [1]. The PE recap market was largely dormant from mid-2022 until SVP closed the MVP merger in December 2024 (~$8.6B, 750+ hospitals, ~$580M EBITDA, Silver Lake + Shore Capital) [6]. Buyers — Mars Veterinary Health (VCA/Banfield/BluePearl), PetVet (KKR), AmeriVet (AEA), NVA (JAB), and Western Veterinary Partners — are paying full price for clean multi-doctor assets and compressing offers on solo, owner-dependent, and rural practices [3][5].
Multiples by size
How veterinary practice multiples shift with EBITDA size
The single biggest determinant of multiple is size. The same business at 4x sub-$1M EBITDA can fetch 7x once it crosses $5M — same operations, different buyer pool.
| Adjusted EBITDA range | Multiple range | What's typical here |
|---|---|---|
| Under $250K Adj. EBITDA — solo / single DVM | 3.5x – 5.0x | Individual buyer pool, SBA-financed, fully owner-dependent — solo DVM practices have no transferable production engine; PE platforms decline to bid and transition contracts of 2–5 years are routinely required. |
| $250K – $500K Adj. EBITDA — 2 DVMs | 6.0x – 7.5x | Multi-doctor lift is active but the EBITDA is still below the PE platform sweet spot; regional consolidators and the lower end of PetVet's published band apply, with 75% cash / 15% rollover / 10% earnout as the typical structure. |
| $500K – $1M Adj. EBITDA — 3+ DVMs, wellness plan adoption | 8.0x – 12.0x | PE add-on sweet spot; associate-led production with transferable management and wellness plan penetration. Ackerman Q2 2025 noted some corporate deals clearing 12.5x at the top of this band. |
| $1M+ Adj. EBITDA — specialty/ER mix or premium multi-doctor GP | 12.0x – 15.0x | Mahan Law's premium tier; PetVet publicly pays 10x+ for $2M+ EBITDA standouts; platform-tier recaps (Mission Pet Health, Western Veterinary Partners continuation vehicle) priced at 17–18x and high-teens respectively. |
Interactive estimate
Estimate the range for your business
Move the sliders. The estimate reflects how each driver pushes the multiple up or down inside the bands above. Use this as a planning anchor — not a sale price.
The single biggest lever in vet valuation. Solo DVM caps at 3.5–6x; two DVMs lifts the band to 6–7.5x; 3+ DVMs with associate coverage clears 7–9x add-on territory and 10–15x at platform scale.
Recurring wellness plans convert transactional invoicing into predictable revenue, partially hedging the macro invoice-growth headwind. 15%+ of revenue is the threshold corporate underwriters reward.
Specialty referral and emergency hospitals trade in a different multiple universe than GP — higher revenue per visit, stickier referral relationships, and ~75% corporate ownership means more bidders and richer comps.
PE buyers require 2–5 year post-sale employment agreements from owner and key associates. Pre-existing retention contracts on staff DVMs eliminate the biggest underwriting risk and can pull offers toward the high end of the band.
Estimated enterprise value
$3.6M – $5.4M
Implied multiple: 6.0x – 9.0x Adjusted EBITDA
This is a directional estimate, not a formal valuation. Real-world veterinary ranges are narrowed by macro invoice growth (three consecutive negative years 2022–2024), DVM retention contracts, specialty mix, regional buyer density, and the negotiated post-close employment agreement. Ad Astra delivers advisor-grade ranges grounded in named corporate-buyer pricing.
Value drivers
What moves the multiple, specific to veterinary practice
Multi-doctor scale (3–4+ DVMs)
+3.0x – 5.0xThe defining lever in veterinary valuation. A 3–4+ DVM practice reduces key-person risk and gives PE underwriters a transferable clinical operation — one whose cash flow survives the owner's exit. Solo practices trade at 3.5–6x; multi-doctor practices clear 7–9x as regional add-ons; the jump is steepest at the 3-DVM threshold where the owner moves from solo provider to clinical director [1][5].
The mechanism: PE buyers underwrite associate-driven production. When associates carry 30–40%+ of clinical revenue, the practice can survive ownership transition without client or revenue leakage. That transferability is what commands platform-tier pricing.
$1M+ EBITDA scale — the PE sweet spot
+3.0x – 6.0xPE's hard underwriting threshold. Mahan Law cites 12–15x for $1M+ EBITDA practices; PetVet (KKR) publicly pays 10x+ for $2M+ EBITDA standouts; the SVP/MVP platform was built on this accumulation [5][7]. Below $500K EBITDA the buyer pool is mostly individuals; at $1M+ four named consolidators compete — Mission Pet Health, PetVet, AmeriVet, and NVA — which is the structural reason for the multiple re-rating [3][6].
Sellers near this threshold should invest in associate hiring and wellness plan penetration as a deliberate valuation strategy before initiating a process.
Specialty / emergency / exotic mix
+1.0x – 3.0xSpecialty referral and emergency hospitals operate in a fundamentally different market: higher revenue per visit, stickier client and referral relationships, and — critically — ~75% corporate ownership in the specialty/ER tier versus 25–50% of GP practices [3]. More corporate ownership means more bidders on every deal.
SovDoc 2025 cites specialty/ER at 12x+ as a baseline. Practices with meaningful specialty mix (internal medicine, oncology, surgery, exotics) that also carry a GP base earn a blended multiple above the pure-GP band [4][10].
Wellness plan recurring revenue base
+0.5x – 1.5xWellness plans (preventive packages, vaccination memberships, annual exam bundles) convert transactional invoicing into recurring, predictable revenue. This matters especially now: with negative invoice growth three years running, recurring plan revenue partially insulates EBITDA from the macro headwind [1].
Evergreen Q1 2025 flags wellness penetration above 15% of revenue as the threshold the recap underwriters reward. Track plan attach rate (% of active clients enrolled) and annual churn — buyers will build both into their DCF models [2].
DVM retention / transition employment contracts
+1.0x – 2.0xPE platforms underwrite continuity. Pre-signed 2–5 year employment agreements with the owner DVM and key associates eliminate the biggest underwriting fear: a production cliff on day one post-close. Ackerman Q1 2025 data confirms that multi-year employment agreements are now structurally required by major platforms — not optional [1].
Practices where associates are already under multi-year contracts earn the upper end of the multiple band because the buyer's continuity risk is pre-priced and documented before LOI.
Solo owner-dependency — the DVM cap
-3.0x – 5.0x (caps at 3.5–6x)A single-DVM, owner-reliant practice has no transferable production engine. The buyer is effectively buying a job, not a business. Serenity Vet's published worked example values such a practice at ~3.5x EBITDA to an SBA-funded individual buyer — the PE-corporate pool simply declines to bid [9].
The structural cap: SBA financing tops out at ~$5M deal size, which means a solo practice earning $500K+ EBITDA is priced out of SBA routes and yet too owner-dependent for corporate routes. This is the worst-valued quadrant in veterinary M&A.
Sub-$1M revenue / thin EBITDA
Caps buyer pool at individualsBelow ~$1M revenue, corporate underwriters won't run a process — the deal economics don't justify the diligence spend. The valuation math flips from EBITDA-based PE math (7–15x) to SDE-based individual-buyer math: 2.32–2.85x SDE per Peak Business Valuation's published benchmarks [4][9].
The practical implication for owners near this threshold: adding one associate DVM to grow revenue past $1.5M can trigger a 3–4x multiple re-rating on the same underlying EBITDA — the highest-ROI capital deployment in vet practice M&A.
Weak staffing continuity / no relief coverage
-1.0x – 2.0xA single licensed DVM and no relief network means clinical operations halt the moment the owner steps out. Buyers either re-price down or require an extended retention package paid out as earnout rather than cash at close — effectively deferring 15–25% of consideration contingent on the owner staying.
The fix is operational: build a relief DVM rotation at least 18 months before a planned sale, document the shift log, and demonstrate that gross revenue holds steady during owner absences. That record supports a clean transition narrative in diligence.
Macro: negative invoice growth, three years running
Sector-wide compression vs. 2021 peakUS veterinary invoice growth was negative in 2022, 2023, and 2024 — down more than 2% per year on average. Ackerman Group calls this "the variable that will determine valuation trends for years." [1] This is the single most important reason why 2021 platform multiples are not the comparable today.
The mitigant inside your own practice: wellness plan penetration, specialty mix, and DVM retention contracts each partially hedge this macro and earn individual multiple premiums even with the sector-wide headwind. Practices with 15%+ wellness plan penetration and 3+ DVMs demonstrably decouple from the invoice-growth drag [2][4].
Buyer landscape
Who is actively buying veterinary practice
Named PE platforms, strategic acquirers, and consolidators active in the space in the last 12 months. Multiples paid by these buyers anchor the high end of our range.
Mars Veterinary Health (VCA · Banfield · BluePearl)
Wholly owned by Mars, Incorporated (private)
The largest global vet operator (~3,000+ clinics including VCA's US GP network, Banfield's PetSmart-located clinics, and BluePearl's specialty/ER footprint); Mars's $9.1B all-cash VCA acquisition in January 2017 (~41% premium to VCA's 30-day VWAP) created the modern corporate-buyer pool and set the foundational pricing precedent for the entire sector.
- Continued BluePearl specialty/ER expansion via tuck-in acquisitions across US urban metros
- VCA GP add-ons across US metros at corporate add-on multiples
- VCA acquisition by Mars closed January 2017 at $9.1B — the sector's foundational corporate-pool event
Mission Pet Health (SVP + Mission/Midwest Veterinary Partners)
Backed by Silver Lake and Shore Capital Partners
The defining recap of the cycle: SVP merged with MVP in December 2024 to form Mission Pet Health — ~$8.6B platform, 750+ hospitals, ~$580M EBITDA, priced at 17–18x EBITDA per press reporting (~14.8x implied on disclosed EBITDA). The single most important platform comp for any 2026 vet seller underwriting a corporate bid.
- SVP + MVP merger closed December 2024 at ~$8.6B platform value, 750+ hospitals
- Ongoing GP add-ons with rollover equity now demanded as a condition of joining the platform
- Silver Lake and Shore Capital partnership establishing the cycle's largest vet consolidation vehicle
PetVet Care Centers
Backed by KKR
Mid-market consolidator with the clearest publicly-cited pricing grid in the sector: 7.5–9.5x EBITDA for multi-doctor GPs and 10x+ for $2M+ EBITDA standouts — the single most reusable concrete benchmark for sellers underwriting a corporate offer.
- Active 2024–2025 add-on cadence across US multi-doctor GP practices
- Published 7.5–9.5x EBITDA pricing band for qualifying multi-doctor assets
AmeriVet Veterinary Partners
Backed by AEA Investors
Buyout + joint-venture structures; growing rapidly via portfolio acquisitions. Active for $500K+ EBITDA multi-doctor GPs, with a demonstrated willingness to acquire practice portfolios in a single transaction.
- Acquired 14 practices from Northeast Veterinary Partners, November 2025, growing the network to 186 clinics
- Portfolio-basis acquisition structure signals readiness to absorb both individual and multi-practice packages
National Veterinary Associates (NVA)
Backed by JAB Holding Company
One of the largest US vet groups by hospital count; still an active buyer of GP and specialty assets where antitrust permits, though FTC scrutiny on the Ethos specialty acquisition and shelved IPO plans have moderated the pace of activity.
- Ethos Veterinary Health specialty acquisition under FTC review (delayed)
- IPO plans shelved amid 2023–2024 market conditions
Western Veterinary Partners
Backed by Tyree & D'Angelo Partners
Hybrid roll-up model; the continuation vehicle that recapped WVP in 2025 priced at a 'high-teens EBITDA multiple' — the cleanest platform-tier print outside SVP/MVP and the key reference for any seller positioning to a recap at scale.
- Continuation vehicle recap, 2025, priced at a 'high-teens EBITDA multiple' (Octus / Secondaries Investor)
Individual / SBA-Funded Buyers
The dominant buyer type for solo and sub-$500K EBITDA practices; SBA 7(a) financing caps the deal at approximately $5M total consideration, pricing the buyer pool into the 3.5–6x EBITDA band for owner-dependent assets.
- Primary buyer for solo/single-DVM practices under $1M revenue — Illustrative: solo rural GP at $160K EBITDA cleared 3.5x, 90% cash / 10% seller note (Serenity Vet worked example)
Regional / Independent Consolidators
Smaller regional platforms and independent sponsors acquiring 2–3 DVM practices in the $250K–$500K EBITDA range where the major PE platforms are less competitive; typically pay 6–8x EBITDA with heavier earnout components.
- Active in suburban multi-DVM markets where Mission Pet Health / PetVet are less focused
- Typical deal profile: $2–4M revenue, 2–3 DVMs, suburban metro, 75% cash / 15% rollover / 10% earnout
Deal structure
Headline price is one number. The structure is the deal.
Headline price is one number. The actual deal is structure — how total consideration splits across cash at close, rollover equity, earnout, and (almost universally in vet) a multi-year employment agreement that re-prices effective consideration if the owner DVM walks early. Ackerman Group's Q1 2025 benchmark pegs cash at close at ~71% of total consideration for veterinary transactions; major platforms — Mission Pet Health especially — now demand rollover equity from sellers as a condition of going on the buyer's roster [1].
The structures below reflect the typical pattern for $500K–$2M EBITDA multi-doctor GP sales to PE-backed platforms in 2025–2026. Platform-tier recaps carry materially more rollover; SBA-financed solo sales to individual buyers skew the opposite way (90% cash, 10% seller note).
Typical breakdown
- Cash at close
- 65–75%
- Rollover equity
- 15–25%
- Earnout
- 5–15%
- Multi-year employment agreement
- Not a dollar component but structurally load-bearing
- Seller note / working capital adjustment
- 0–5% / ±2–4%
Ackerman benchmark 71% Q1 2025; senior debt plus PE equity check. Specialty/ER and $1M+ EBITDA assets land at the upper end; sub-$500K EBITDA add-ons land lower.
Now effectively mandatory at Mission Pet Health (SVP/MVP) and increasingly required at PetVet and AmeriVet; held in the holdco — the seller's 'second bite' is the platform's next recap or IPO.
12–36 month performance period tied to revenue, EBITDA, or DVM retention targets; more prominent on assets with key-person risk or a weak post-close transition plan.
2–5 year post-sale employment of owner DVM and named associates; early departure typically claws back earnout and can trigger rollover discount — negotiate the comp grid and clinical autonomy clauses before LOI, not after.
Seller notes are uncommon in PE platform deals (more typical in SBA-financed individual-buyer sales); working capital peg is always re-negotiated near close — pre-set it at LOI to avoid a surprise at closing.
Recent comps (anonymized)
Representative veterinary practice transactions
| Profile | Closed | Multiple | Buyer | Structure |
|---|---|---|---|---|
| ~$580M EBITDA across 750+ hospitals · Southern Veterinary Partners + Mission/Midwest Veterinary Partners platform-of-platforms merger forming Mission Pet Health | 2024 Q4 | ~14.8x implied (17–18x per press reporting) | Silver Lake + Shore Capital (PE recap / merger) | Merger — significant rollover at the holdco level |
| Hybrid roll-up GP/specialty platform · Western Veterinary Partners continuation vehicle | 2025 | "high-teens EBITDA multiple" | Tyree & D'Angelo continuation vehicle (single-name CV) | Continuation vehicle — LP roll |
| 14-practice portfolio · Northeast US · AmeriVet acquires from Northeast Veterinary Partners | 2025 Q4 | Undisclosed (portfolio basis) | AmeriVet Veterinary Partners (AEA Investors) | Portfolio acquisition |
| $800K rev / $160K EBITDA · solo DVM · owner-dependent · rural Midwest · 12 years of operation. Illustrative model based on Serenity Vet published worked example. | 2025 Q1 | 3.5x EBITDA | Individual buyer (SBA 7(a) financed) | 90% cash / 10% seller note |
| $2.2M rev / $450K EBITDA · 2 DVMs · suburban metro · multi-doctor lift active. Illustrative model based on Transitions Elite 7–9x range. | 2025 Q2 | 7.5x EBITDA | Regional consolidator (PetVet / AmeriVet tier) | 75% cash / 15% rollover / 10% earnout |
| $4.5M rev / $900K EBITDA · 4 DVMs · wellness plan adoption · affluent metro. Illustrative model based on Ackerman Q2 2025 and PetVet 10x+ threshold. | 2024 Q4 | 10.0x EBITDA | PE-backed platform (NVA / PetVet tier) | 71% cash / 19% rollover / 10% earnout |
| $7M rev / $1.4M EBITDA · multi-DVM GP + specialty referral · urban metro. Illustrative model based on Mahan Law 12–15x and Ackerman Q2 2025 high end. | 2025 Q1 | 12.5x EBITDA | Strategic consolidator (Mars / NVA / Mission Pet Health add-on tier) | 70% cash / 20% rollover / 10% earnout |
Profiles aggregated from public PE press releases and internal Ad Astra advisory data. Cited where attribution is public.
Methodology
How valuation methods apply to veterinary practice
Comparable transactions — the anchor for veterinary
Comparable transactions is the primary method for veterinary because the named corporate pool is small and the pricing grids are publicly disclosed. PetVet's 7.5–9.5x band for multi-doctor GPs (and 10x+ for $2M+ EBITDA standouts), Mahan Law's 12–15x tier for $1M+ EBITDA assets, and the SVP/MVP 17–18x platform print together create a three-tier pricing ladder that is more legible than in almost any other lower-middle-market vertical [5][6][7].
We build the comp set on two axes: doctor count (solo vs. 2 vs. 3+) and specialty mix (pure GP vs. GP+specialty vs. specialty/ER). A $1M EBITDA solo GP and a $1M EBITDA 3-DVM specialty referral hospital are not in the same comp set — the market prices them 6–8 turns apart. Named-buyer benchmarks frame the range; private add-on data from Ackerman Q1/Q2 2025 fills in the middle [1][3].
DCF — pricing the invoice-growth headwind
DCF is the second method precisely because of the macro. With veterinary invoice growth negative for three consecutive years (2022, 2023, 2024 — down >2%/year), terminal-value assumptions must be defended explicitly rather than assumed away [1]. We model three scenarios: (1) base case — 2025–2027 invoice growth flat-to-slightly-negative, recovering to +1–2% by 2028; (2) bear case — another 1–2 years of negative invoice growth before stabilization; (3) bull case — wellness plan penetration above 20% partially insulates the practice from invoice-level headwinds.
Terminal value is anchored to a market exit multiple — typically the PetVet 7.5–9.5x band for a qualifying multi-doctor asset — not a perpetual-growth assumption. This is where wellness plan penetration earns its DCF premium: it shifts the sensitivity from 'how bad does invoice growth get' to 'what fraction of revenue is retained through plan renewals' [2][4].
Asset-based — the floor check
Asset value (equipment, leasehold improvements, inventory, working capital, the goodwill of the patient list) materially understates operating value for any healthy practice. We use asset-based as a floor sanity check: if the asset-based value lands within ~30% of the comp-based value, the operating EBITDA quality should be re-tested — usually owner-DVM compensation is under-normalized or wellness plan attach rate is being mis-counted in the revenue bridge [2].
For solo practices selling to individual buyers in SBA processes, asset-based becomes structurally relevant because SBA lenders model the loan-to-value against tangible assets and goodwill of the patient list — typically capped at ~$5M total deal size, which constrains the multiple more than the buyer's willingness to pay [9].
Sell-side adjustments
The adjustments that protect — and grow — your reported EBITDA
Each item below is something we expect to debate with a buyer's QoE provider. Document them yourself, with backup, before going to market.
Owner-DVM production compensation normalized to market
+$50K – $300KOwner DVMs typically take W-2 production compensation plus distributions. The buyer rebuilds owner comp to a market clinical wage for a replacement DVM — AVMA and industry recruiter benchmarks typically land at $130K–$200K depending on geography and specialty. The delta between what the owner took and market replacement cost is an add-back to EBITDA; defend it with a quoted replacement search and job description.
Family members on payroll above market
+$20K – $120KSpouse on payroll as practice manager at $90K when comparable market is $55K; adult children with W-2s but no defensible role. Strip the above-market portion (or the full comp if no real function). Document the actual responsibilities, comp the comparable role on Glassdoor/Indeed, and exclude unused PTO accruals from the add-back.
Owner-occupied real estate at above/below market rent
+$30K – $150KIf the owner DVM also owns the building and charges below-market rent to the practice, EBITDA is artificially inflated — the buyer normalizes to market rent and applies the multiple to the lower number. The opposite case (above-market related-party rent) is normalized down. Resolve before LOI with a third-party rent comp or commit to a market-rate triple-net lease at close.
Deferred equipment capex (dental units, anesthesia, imaging)
-$30K – $250KThe negative add-back. If the dental machine is 12 years old, the in-house lab analyzer needs replacement, or digital imaging is overdue — the buyer's QoE team bakes the replacement cost into the deal model and deducts it from purchase price or the working capital adjustment. Get ahead of it with a documented 5–7 year clinical equipment refresh schedule presented at kickoff.
Owner truck/vehicle and family vehicles run through P&L
+$10K – $40KThe owner's vehicle (and often a spouse's) booked as a practice expense with fuel, insurance, and maintenance run through the P&L. Strip the personal-use portion; legitimate large-animal ambulance or house-call vehicle costs remain as operating expense.
Associate DVM sign-on bonuses and retention normalization
Varies — case by caseOne-time sign-on bonuses paid to lock in associate DVMs ahead of a sale process are add-backs to normalized EBITDA; recurring retention bonuses tied to long-term incentive plans are operating costs and stay in. The buyer's QoE team will make this distinction — pre-emptively bucket each payment as one-time vs. recurring with contemporaneous backup documentation.
Hospital admin / personal expenses run through P&L
+$15K – $100KCE travel that doubled as vacation, professional dues, country club memberships, family meals booked as 'team building.' Strip with contemporaneous backup — aggressive add-backs without documentation collapse in diligence and damage seller credibility on the rest of the quality-of-earnings process.
FAQ
Common questions about veterinary practice valuation
Veterinary Practice vs comparable industries
Ready to actually sell?
Get an owner-grade range for your veterinary practice
A confidential 30-minute call with Clayton or Joe gives you a real range, the adjustments we'd apply to your reported EBITDA, and the one or two moves that close the gap fastest.
- [1] Ackerman Group — Q1 2025 Veterinary Industry Market Update
- [2] Ackerman Group — EBITDA in Vet Valuations
- [3] Octus — Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure (2025)
- [4] SovDoc — How to Value a Veterinary Practice (2025)
- [5] Transitions Elite — PetVet Purchase Price (2025)
- [6] Transitions Elite — Southern Veterinary Partners Acquisition
- [7] Mahan Law — Buying a Veterinary Practice: Practice Valuation — What Should I Pay?
- [8] Yahoo Finance — Candy maker Mars is biggest vet (Mars / VCA analysis)
- [9] Serenity Vet — How to Value a Veterinary Practice: Complete 2026 Guide
- [10] First Page Sage — Veterinary Practice EBITDA Valuation Multiples
Multiple ranges represent typical lower middle market transactions; individual deals may fall outside the band based on buyer thesis, deal structure, and seller-specific factors. This page is informational and not a formal valuation opinion.